202 related articles for article (PubMed ID: 38139151)
21. Inhibition of YAP/TAZ-TEAD activity induces cytotrophoblast differentiation into syncytiotrophoblast in human trophoblast.
Mizutani T; Orisaka M; Miyazaki Y; Morichika R; Uesaka M; Miyamoto K; Yoshida Y
Mol Hum Reprod; 2022 Sep; 28(10):. PubMed ID: 35993908
[TBL] [Abstract][Full Text] [Related]
22. Hippo-YAP/TAZ signalling in organ regeneration and regenerative medicine.
Moya IM; Halder G
Nat Rev Mol Cell Biol; 2019 Apr; 20(4):211-226. PubMed ID: 30546055
[TBL] [Abstract][Full Text] [Related]
23. New insights into the ambivalent role of YAP/TAZ in human cancers.
Luo J; Deng L; Zou H; Guo Y; Tong T; Huang M; Ling G; Li P
J Exp Clin Cancer Res; 2023 May; 42(1):130. PubMed ID: 37211598
[TBL] [Abstract][Full Text] [Related]
24. Calmodulin activates the Hippo signaling pathway by promoting LATS1 kinase-mediated inhibitory phosphorylation of the transcriptional coactivator YAP.
Thines L; Gorisse L; Li Z; Sayedyahossein S; Sacks DB
J Biol Chem; 2022 May; 298(5):101839. PubMed ID: 35307353
[TBL] [Abstract][Full Text] [Related]
25. Potential Natural Biomolecules Targeting JAK/STAT/SOCS Signaling in the Management of Atopic Dermatitis.
Kopalli SR; Annamneedi VP; Koppula S
Molecules; 2022 Jul; 27(14):. PubMed ID: 35889539
[TBL] [Abstract][Full Text] [Related]
26. Stabilization of Motin family proteins in NF2-deficient cells prevents full activation of YAP/TAZ and rapid tumorigenesis.
Wang Y; Zhu Y; Gu Y; Ma M; Wang Y; Qi S; Zeng Y; Zhu R; Wang X; Yu P; Xu J; Shu Y; Yu FX
Cell Rep; 2021 Aug; 36(8):109596. PubMed ID: 34433060
[TBL] [Abstract][Full Text] [Related]
27. Proliferation of hepatic stellate cells, mediated by YAP and TAZ, contributes to liver repair and regeneration after liver ischemia-reperfusion injury.
Konishi T; Schuster RM; Lentsch AB
Am J Physiol Gastrointest Liver Physiol; 2018 Apr; 314(4):G471-G482. PubMed ID: 29351389
[TBL] [Abstract][Full Text] [Related]
28. Complex roles of Hippo-YAP/TAZ signaling in hepatocellular carcinoma.
Shi H; Zou Y; Zhong W; Li Z; Wang X; Yin Y; Li D; Liu Y; Li M
J Cancer Res Clin Oncol; 2023 Nov; 149(16):15311-15322. PubMed ID: 37608027
[TBL] [Abstract][Full Text] [Related]
29. Pharmacodynamics of Janus kinase inhibitors for the treatment of atopic dermatitis.
Calabrese L; Chiricozzi A; De Simone C; Fossati B; D'Amore A; Peris K
Expert Opin Drug Metab Toxicol; 2022 May; 18(5):347-355. PubMed ID: 35796377
[TBL] [Abstract][Full Text] [Related]
30. YAP/TAZ for cancer therapy: opportunities and challenges (review).
Guo L; Teng L
Int J Oncol; 2015 Apr; 46(4):1444-52. PubMed ID: 25652178
[TBL] [Abstract][Full Text] [Related]
31. YAP/TAZ maintain the proliferative capacity and structural organization of radial glial cells during brain development.
Lavado A; Gangwar R; Paré J; Wan S; Fan Y; Cao X
Dev Biol; 2021 Dec; 480():39-49. PubMed ID: 34419458
[TBL] [Abstract][Full Text] [Related]
32. YAP and TAZ Negatively Regulate Prox1 During Developmental and Pathologic Lymphangiogenesis.
Cho H; Kim J; Ahn JH; Hong YK; Mäkinen T; Lim DS; Koh GY
Circ Res; 2019 Jan; 124(2):225-242. PubMed ID: 30582452
[TBL] [Abstract][Full Text] [Related]
33. EP300 promotes lung cancer cell proliferation by regulating the oncogenic transcription of Hippo-YAP signaling pathway.
Li S; Shi J; Wang L; Zhang D; Zhang H
Biochem Biophys Res Commun; 2024 Jan; 692():149330. PubMed ID: 38048728
[TBL] [Abstract][Full Text] [Related]
34. Yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ) mediate cell density-dependent proinflammatory responses.
Zhang Q; Han X; Chen J; Xie X; Xu J; Zhao Y; Shen J; Hu L; Xu P; Song H; Zhang L; Zhao B; Wang YJ; Xia Z
J Biol Chem; 2018 Nov; 293(47):18071-18085. PubMed ID: 30315101
[TBL] [Abstract][Full Text] [Related]
35. Hippo pathway inhibition by blocking the YAP/TAZ-TEAD interface: a patent review.
Crawford JJ; Bronner SM; Zbieg JR
Expert Opin Ther Pat; 2018 Dec; 28(12):867-873. PubMed ID: 30482112
[No Abstract] [Full Text] [Related]
36. YAP and TAZ play a crucial role in human erythrocyte maturation and enucleation.
Damkham N; Lorthongpanich C; Klaihmon P; Lueangamornnara U; Kheolamai P; Trakarnsanga K; Issaragrisil S
Stem Cell Res Ther; 2022 Sep; 13(1):467. PubMed ID: 36076260
[TBL] [Abstract][Full Text] [Related]
37. Deubiquitinating Enzyme USP9X Suppresses Tumor Growth via LATS Kinase and Core Components of the Hippo Pathway.
Toloczko A; Guo F; Yuen HF; Wen Q; Wood SA; Ong YS; Chan PY; Shaik AA; Gunaratne J; Dunne MJ; Hong W; Chan SW
Cancer Res; 2017 Sep; 77(18):4921-4933. PubMed ID: 28720576
[TBL] [Abstract][Full Text] [Related]
38. New insights into YAP/TAZ nucleo-cytoplasmic shuttling: new cancer therapeutic opportunities?
Shreberk-Shaked M; Oren M
Mol Oncol; 2019 Jun; 13(6):1335-1341. PubMed ID: 31050214
[TBL] [Abstract][Full Text] [Related]
39. Increased expression of yes-associated protein/YAP and transcriptional coactivator with PDZ-binding motif/TAZ activates intestinal fibroblasts to promote intestinal obstruction in Crohn's disease.
Ou W; Xu W; Liu F; Guo Y; Huang Z; Feng T; Liu CY; Du P
EBioMedicine; 2021 Jul; 69():103452. PubMed ID: 34186485
[TBL] [Abstract][Full Text] [Related]
40. YAP and the Hippo pathway in cholangiocarcinoma.
Sugihara T; Isomoto H; Gores G; Smoot R
J Gastroenterol; 2019 Jun; 54(6):485-491. PubMed ID: 30815737
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
